Seelos Therapeutics, Inc. — Operating Income by Fiscal Year

15 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/81e88243-e354-4c30-b7c5-de393c63d270/serie/operating-income

Fiscal year	Operating Income	Period	Evidence
FY 2023	$-40.5M	2023-01-01 – 2023-12-31	evidence 0001410578-24-000140
FY 2022	$-70.9M	2022-01-01 – 2022-12-31	evidence 0001104659-23-030733
FY 2021	$-61.7M	2021-01-01 – 2021-12-31	evidence 0001136261-22-000156
FY 2020	$-18.8M	2020-01-01 – 2020-12-31	evidence 0001136261-21-000034
FY 2019	$-29.7M	2019-01-01 – 2019-12-31	evidence 0001136261-20-000092
FY 2018	$-3.2M	2018-01-01 – 2018-12-31	evidence 0001136261-20-000092
FY 2017	$-10.7M	2017-01-01 – 2017-12-31	evidence 0001017491-18-000026
FY 2016	$-13.7M	2016-01-01 – 2016-12-31	evidence 0001017491-18-000026
FY 2015	$-21.4M	2015-01-01 – 2015-12-31	evidence 0001017491-16-000112
FY 2014	$-22.6M	2014-01-01 – 2014-12-31	evidence 0001017491-15-000032
FY 2013	$-17.4M	2013-01-01 – 2013-12-31	evidence 0001017491-14-000052
FY 2012	$-25.0M	2012-01-01 – 2012-12-31	evidence 0001017491-14-000052
FY 2011	$-18.3M	2011-01-01 – 2011-12-31	evidence 0001017491-14-000052
FY 2010	$-21.4M	2010-01-01 – 2010-12-31	evidence 0001193125-13-111046
FY 2009	$-3.8M	2009-01-01 – 2009-12-31	evidence 0001144204-12-014548

Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

Seelos Therapeutics, Inc. — all facts · Revenue · Net Income